Enlivex Therapeutics Ltd.

As of June 18, 2025, the technical trend is neutral with mixed signals, as weekly indicators show mild bullishness while monthly and daily indicators suggest bearishness, leading to an overall sideways outlook.

As of March 2022, the management team of Enlivex Therapeutics Ltd. includes Executive Chairman Mr. Shai Novik and Directors Mr. Michel Habib, Mr. Baruch Halpert, Dr. Bernhard Kirschbaum, Dr. Hyun Gyu Lee, and Mr. Sangwoo Lee.

Enlivex Therapeutics Ltd. is an Israel-based clinical-stage company specializing in cell immunotherapy to develop treatments for immune hyper-responses. It has a market cap of $24.57 million and reported a net loss of $3 million in Q1 2025.

As of Jun 18, Enlivex Therapeutics Ltd. has a market capitalization of 24.57 million and reported net sales of 0.00 million with a net profit of -14.33 million over the last four quarters. Shareholder's funds are 23.59 million, and total assets amount to 27.69 million.